-
公开(公告)号：US09895367B2
公开(公告)日：2018-02-20
申请号：US14003445
申请日：2011-08-10
申请人： Durga Maheswari Parvataneni , Siddhartha Yedluri , Venkata Satyanarayana Appadwedula , Kali Satya Bhujanga Rao , Venkaiah Chowdary Nannapaneni
发明人： Durga Maheswari Parvataneni , Siddhartha Yedluri , Venkata Satyanarayana Appadwedula , Kali Satya Bhujanga Rao , Venkaiah Chowdary Nannapaneni
CPC分类号： A61K31/506 , A61K9/0053 , A61K9/08 , A61K9/107 , A61K9/4858 , A61K9/4866 , A61K47/10 , A61K47/14 , A61K47/44
摘要： An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
-
2.发明申请NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT 审中-公开新4-（TETRAZOL-5-YL） - 喹诺酮衍生物作为抗癌剂公开(公告)号：US20120172380A1
公开(公告)日：2012-07-05
申请号：US13330304
申请日：2011-12-19
申请人： Durga prasad Konakanchi , Subba Rao Pula , Lakshmi Ananthaneni , Pulla Reddy Muddasani , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
发明人： Durga prasad Konakanchi , Subba Rao Pula , Lakshmi Ananthaneni , Pulla Reddy Muddasani , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
IPC分类号： A61K31/517 , A61P35/00
CPC分类号： A61K31/517
摘要： The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man.
摘要翻译： 本发明涉及具有抗增殖活性如抗癌活性的式I的取代的4-（四唑-5-基） - 喹唑啉衍生物或其药学上可接受的盐，因此可用于治疗 人或动物的身体。 本发明还涉及制备取代的4-（四唑-5-基） - 喹唑啉衍生物的方法，用于制备含有该化合物的药物组合物及其在制备药物中的用途，所述药物在其中产生抗增殖作用 温血动物如人。
-
公开(公告)号：US20150079642A1
公开(公告)日：2015-03-19
申请号：US14391000
申请日：2012-04-12
申请人： Baby Rani Polavarapu , Suneel Kumar Battula , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
发明人： Baby Rani Polavarapu , Suneel Kumar Battula , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
IPC分类号： C12P17/18
CPC分类号： C12P17/189 , C12P17/188 , C12R1/55
摘要： The present invention provides a novel method for producing rapamycin by submerged fermentation which comprises cultivating Streptomyces hygroscopicus (CBS 773.72) and mutants thereof. The present invention provides a high yielding mutant culture MTCC5681 from Streptomyces hygroscopicus CBS 773.72. This culture is capable of producing rapamycin more efficiently than the cultures Streptomyces hygroscopicus from sources like ATCC, NRRL etc which have been reported so far.
摘要翻译： 本发明提供一种通过浸没发酵生产雷帕霉素的新方法，其包括培养吸水链霉菌（CBS 773.72）及其突变体。 本发明提供了来自吸水链霉菌CBS 773.72的高产突变培养物MTCC5681。 这种培养物能够比来自诸如ATCC，NRRL等来源的培养物吸湿链霉菌（Streptomyces hygroscopicus）更有效地产生雷帕霉素。
-
4.发明申请PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID 审中-公开制备S-2-羟基-3-甲氧基-3,3-二苯基丙酸的方法公开(公告)号：US20130184490A1
公开(公告)日：2013-07-18
申请号：US13814038
申请日：2010-08-04
申请人： Amala Kompella , Kali Satya Bhujanga Rao Adibhatla , Veera Swamy Balina , Srinivasu Kasa , Venkaiah Chowdary Nannapaneni
发明人： Amala Kompella , Kali Satya Bhujanga Rao Adibhatla , Veera Swamy Balina , Srinivasu Kasa , Venkaiah Chowdary Nannapaneni
IPC分类号： C07C51/09
CPC分类号： C07C51/09 , C07B2200/07 , C07C51/02 , C07C51/412 , C07C67/31 , C07D303/48 , C07C59/66 , C07C69/734
摘要： Disclosed is a process for the preparation of S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (I) the key intermediate for the preparation of Ambrisentan [(+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid]. Ambrisentan of the formula (IA) is approved under the trademark “Letairis ®” by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension (PAH).
摘要翻译： 公开了一种制备S-2-羟基-3-甲氧基-3,3-二苯基丙酸（I）的方法，该方法是制备安立生坦[（+） - 2（S） - （4,6-二 -2,3-二甲基嘧啶-2-基氧基）-3-甲氧基-3,3-二苯基丙酸]。 式（IA）的安立生坦由美国食品和药物管理局以商标“Letairis®”批准用于治疗肺动脉高压（PAH）。
-
公开(公告)号：US20130059889A1
公开(公告)日：2013-03-07
申请号：US13581872
申请日：2010-03-08
申请人： Durga Prasad Konakanchi , Buchappa Gongalla , Kotayya Babu Sikha , Chandrasekar Kandaswamy , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
发明人： Durga Prasad Konakanchi , Buchappa Gongalla , Kotayya Babu Sikha , Chandrasekar Kandaswamy , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
IPC分类号： C07D401/04 , A61P35/00 , A61K31/454
CPC分类号： C07D401/04
摘要： Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed.
-
公开(公告)号：US20120058200A1
公开(公告)日：2012-03-08
申请号：US13319050
申请日：2009-05-15
申请人： Pulla Reddy Muddasani , Sambasiva Rao Talasila , Bhujanga Roa Adibhatla Kali Satya , Venkata Reddy Satti , Anil Kumar Lingamaneni , Venkaiah Chowdary Nannapaneni
发明人： Pulla Reddy Muddasani , Sambasiva Rao Talasila , Bhujanga Roa Adibhatla Kali Satya , Venkata Reddy Satti , Anil Kumar Lingamaneni , Venkaiah Chowdary Nannapaneni
CPC分类号： C01F17/005 , A61K33/24 , C01P2002/72 , C01P2002/82 , C01P2002/88
摘要： Present invention relates to a process for the preparation and pharmaceutical usage of dihydrate form of lanthanum carbonate. Present process produces lanthanum carbonate dihydrate (La2(CO3)3.2H2O) free of lanthanum hydroxycarbonate and is stable at ambient condition. Lanthanum carbonate dihydrate exhibit improved performance over standard lanthanum carbonate tetrahydrate in phosphate binding studies. Lanthanum carbonate dihydrate is useful for the treatment of hyperphosphataemia in patients with renal failure.
摘要翻译： 本发明涉及碳酸镧二水合物的制备和药物应用的方法。 本方法生产的碳酸镧二水合物（La2（CO3）3.2H2O）不含羟基碳酸镧，在环境条件下稳定。 碳酸镧二水合物在磷酸盐结合研究中表现出比标准的四水合碳酸镧改善的性能。 碳酸镧二水合物可用于治疗肾功能衰竭患者的高磷酸血症。
-
公开(公告)号：US09750700B2
公开(公告)日：2017-09-05
申请号：US13166499
申请日：2011-06-22
IPC分类号： A61K31/44 , A61K31/444 , C07D213/06 , C07D221/16 , A61K9/20 , A61K9/16
CPC分类号： A61K9/2013 , A61K9/1688
摘要： The invention relates to an oral pharmaceutical composition comprising, greater than 80% of Imatinib, by weight based on the total weight of the composition and the process for preparation thereof.
-
公开(公告)号：US09365880B2
公开(公告)日：2016-06-14
申请号：US14391000
申请日：2012-04-12
申请人： Baby Rani Polavarapu , Suneel Kumar Battula , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
发明人： Baby Rani Polavarapu , Suneel Kumar Battula , Kali Satya Bhujanga Rao Adibhatla , Venkaiah Chowdary Nannapaneni
CPC分类号： C12P17/189 , C12P17/188 , C12R1/55
摘要： The present invention provides a novel method for producing rapamycin by submerged fermentation which comprises cultivating Streptomyces hygroscopicus (CBS 773.72) and mutants thereof. The present invention provides a high yielding mutant culture MTCC5681 from Streptomyces hygroscopicus CBS 773.72. This culture is capable of producing rapamycin more efficiently than the cultures Streptomyces hygroscopicus from sources like ATCC, NRRL etc which have been reported so far.
摘要翻译： 本发明提供一种通过浸没发酵生产雷帕霉素的新方法，其包括培养吸水链霉菌（CBS 773.72）及其突变体。 本发明提供了来自吸水链霉菌CBS 773.72的高产突变培养物MTCC5681。 这种培养物能够比来自诸如ATCC，NRRL等来源的培养物吸湿链霉菌（Streptomyces hygroscopicus）更有效地产生雷帕霉素。
-
公开(公告)号：US09061028B2
公开(公告)日：2015-06-23
申请号：US13397640
申请日：2012-02-15
申请人： Amala Kompella , Adibhatla Kali Satya Bhujanga Rao , Sreenivas Rachakonda , Venugopala Krishna Gampa , Venkaiah Chowdary Nannapaneni
发明人： Amala Kompella , Adibhatla Kali Satya Bhujanga Rao , Sreenivas Rachakonda , Venugopala Krishna Gampa , Venkaiah Chowdary Nannapaneni
IPC分类号： C07D401/14 , A61K31/506 , C07D233/61
CPC分类号： C07D401/14 , A61K31/506 , C07B2200/13 , C07D233/61
摘要： The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及制备式（I）化合物或其药学上可接受的盐的方法：该方法包括将式（Ⅳ）化合物或其药学上可接受的盐转化为式 I）或其药学上可接受的盐。
-
公开(公告)号：US20130210847A1
公开(公告)日：2013-08-15
申请号：US13397640
申请日：2012-02-15
申请人： Amala Kompella , Adibhatla Kali Satya Bhujanga Rao , Sreenivas Rachakonda , Venugopala Krishna Gampa , Venkaiah Chowdary Nannapaneni
发明人： Amala Kompella , Adibhatla Kali Satya Bhujanga Rao , Sreenivas Rachakonda , Venugopala Krishna Gampa , Venkaiah Chowdary Nannapaneni
IPC分类号： A61K31/506 , C07D233/61 , C07D401/14
CPC分类号： C07D401/14 , A61K31/506 , C07B2200/13 , C07D233/61
摘要： The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.012 秒)
